Estado actual de la vacuna conjugada contra Streptococcus Pneumoniae

Autores/as

  • Hernán Sierra Fernández Instituto de Atención Pediátrica
  • Malka Shultz Faingezicht Instituto de Atención Pediátrica
  • Carolina Soley Gutiérrez Instituto de Atención Pediátrica
  • Silvia Guevara Jiménez Instituto de Atención Pediátrica
  • Adriano Arguedas Mhos Universidad de Ciencias Médicas

DOI:

https://doi.org/10.51481/amc.v48i2.243

Palabras clave:

S. pneumoniae, enfermedad invasora, vacuna conjugada

Resumen

Las infecciones por Streptococcus pneumoniae son frecuentes en la población pediátrica especialmente en los niños menores de 2 años. El S. pneumoniae puede producir infecciones invasoras con una alta tasa de mortalidad y morbilidad como lo son las meningitis bacterianas, la neumonía y bacteremias siendo a la vez el agente que con mayor frecuencia se detecta en el oído medio de niños con otitis media. En la actualidad existe una vacuna conjugada contra esta bacteria que protege contra los siete serotipos de S. pneumoniae más frecuentes en el mundo y que a su vez son los mismos serotipos que presentan una mayor incidencia de resistencia a los antibioticos de uso frecuente. La vacuna no solo protege contra este tipo de infecciones sino que se ha demostrado que disminuye la colonización nasofaringea de los niños que han recibido la vacuna produciendo a su vez, una reducción en el numero de infecciones, por esta bacteria, en poblaciones de personas mayores de 5 años, incluyendo adultos y personas mayores a los 65 años (efecto rebaño). Con base en los serotipos aislados en niños costarricenses con otitis media, se puede calcular que la cobertura de esta vacuna en Costa Rica sería de aproximadamente un 74% e incluyendo mayoritariamente, los serotipos que presentan resistencia antimicrobriana más frecuentemente.

Descargas

Los datos de descargas todavía no están disponibles.

Citas

Preventing pneumococcal disease among infants and young children:recommendations of the Advisory Committee on ImmunizationPractices (ACIP) MMWR 2000; 49:1-38.

MMWR CDC Prevention of pneumococcal disease: recommenda-tions of the Advisory Committee on Immunization Practices (ACIP).1997; 46:1-24.

Peter G, Klein JO. Streptococcus pneumoniae. En: Long SS,Pickering LK, Prober CG, eds. Principles and practice of pediatricinfectious diseases. 2nd ed. Philadelphia: Churchill Livingstone.2003:739-46.

World Health Organization. Pneumococcal vaccine.Wkly EpidemiolReport 2003; 14:110-9

.5.Dagan R, Relamed M, Piglansky L, Greenberg D, Abramson O,Mendelman PM, et al. Reduction of nasopharyngeal carriage of pneu-mococci during the second year of life by a heptavalent conjugatepneumococcal vaccine. J Infect Dis. 1996; 174:1271-78.

Shinefield HR, Black SB. Postlicensure surveillance forHaemophilus influenzae type b invasive disease alter use ofHaemophilus influenzae type b oligosaccharide CRM197 conjugatevaccine in the large defined United Status population: a four yeareight month follow up. Pediatr Infect Dis J. 1995; 14:978-981.

CDC. Progress toward elimination of Haemophilus influenzae type bamong infants and children: United States, 1987-1993. MMWR1994; 43:144-8.

Centers for Disease Control and Prevention. Prevention of pneumo-coccal disease: recommendation of the Advisory Committee onImmunization Practices (ACIP), MMWR. 1997; 46:1-24.

Ulloa R, Avila M, Herrera M, Herrera J, Arguedas A. Invasive pneu-mococcal disease in Costa Rican children: a seven year survey.Pediatr Infect Dis J. 2003; 22:1069-74.

Eskola J, Kilpi T, Palmu A, Jokinen J, Haapakoski J, Herva E, et al.Efficacy of a Pneumococcal conjugate vaccine against acute otitismedia. N Engl J Med. 2001; 344:403-409.

Niemelá M, Uhari M, Möttönen M, Pokka T. Cost arising from otitismedia. Acta Paediatr. 1999; 88:553-556.

Gates GA. Cost-effectiveness considerations in otitis media treat-ment. Otolaryngol Head Neck Surg. 1996; 14:525-530.

Kaplan B, Wandstrat TL, Cunningham JR. Overall cost in the treat-ment of otitis media. Pediatr Infect Dis J. 1997; 16:S9-S11.

Bondy J, Berman S, Glazner J, Lezotte D. Direct expenditures relat-ed to otitis media diagnosis: extrapolations from a pediatric Medicaidcohort. Pediatrics. 2000; 105:1323-1323.

National Committee for Clinical and Laboratory Standards: twelfthinformational supplement. NCCLS document. M100-S12 (ISBN 1-56238-454-6). NCCLS, 940 West Valley Road, Suite 1400, Wayne,Pennsylvania 12807-1898, USA 2002.

Hava DL, Le Mieux J. From nose to lung: the regulation behindStreptococcus pneumoniae virulence factors. Molec Microbiol. 2003;50:1103-10.

Ghaffar F, Friedland I, Mccraken G. Dynamics of nasopharyngealcolonization by S.pneumoniae. Pediatr Infect Dis J. 1999;

: 638-46.70

Brueggemann AB, Peto TE, Crook DW, Butler JC, Kristinsson K,Spratt B. Temporal and geographic stability of the serogroup- specif-ic invasive disease potential of Streptococcus pneumoniae in chil-dren. J Infect Dis. 2004; 190:1203-11.

Fernebro J, Andersson I, Sublett J, Morfeldt E, Novak R, TuomanenE, et al. Capsular expression in Streptococcus pneumoniae negative-ly affects spontaneous and antibiotic-induced lysis and contributes toantibiotic tolerance. J Infect Dis. 2004; 189:328-38. Epub 2003 Dec30.

American Academy of Pediatrics. Pneumococcal Infections En:Pickering LK, ed. Red book: 2003 Report of the Committee onInfectious Diseases. 26th ed. Elk Grove Village, IL: AmericanAcademy of Pediatrics; 2003:496-500.

Arguedas A, Dagan R, Guevara S, Porat N, Soley C, Pérez A, BrillaR. Middle ear fluid Streptococcus pneumoniae serotype distributionin Costa Rican children with otitis media. Pediatr Infect Dis J. 2005;24:631-634.

Arguedas A, Dagan R, Soley C, Loaiza C, Knudsen K, Porat N, PerezA, Brilla E, Herrera ML. Microbiology of otitis media in Costa Ricanchildren, 1999 through 2001. Pediatr Infect Dis J. 2003; 22:1063-8.

Dagan R. Vacunas neumocóccicas conjugadas para prevenir laportación y propagación de neumococos resistentes a los antibióticos.Arch. argent pediatr. 2002:100:19-24.

Vives M, García ME, Saenz P, Mora M, Mata L, Sabharwal H, et al.Nasopharyngeal colonization in Costa Rican children during the firstyear of life. Pediatr Infect Dis J. 1997; 16:852-58.

García JA, Fresnadillo MJ. Dynamics of nasopharyngeal colonizationby potential respiratory pathogens. J Antimicrob Chemother. 2002;50:59-73.

Fattom A, Lue C, Szu SC, Mestecky J, et al. Serum antibody responsein adult volunteers elicited by injection of Streptococcus pneumoniaetype 12F polysaccharide alone or conjugated to diphtheria toxoid.Infect Immun. 1990; 58:2309-12. 27.Nieminen T, Kayhty H, Leroy O, Eskola J. Pneumococcal conju-gate vaccination in toddlers: mucosal antibody response measured ascirculating antibody-secreting cells and as salivary antibodies.Pediatr Infect Dis J. 1999; 18:764-72. 28.Adderson EE. Antibody repertoires in infants and adults: effects ofT-independent and T-dependent immunizations. Springer SeminImmunopathol. 2001; 23:387-403.

Perez-Melgosa M, Ochs HD, Linsley PS, Laman JD, van Meurs M,Flavell R, et al. Carrier-mediated enhancement of cognate T cell help:the basis for enhanced immunogenicity of meningococcal outermembrane protein polysaccharide conjugate vaccine. Eur J Immunol.2001; 31:2373-81.

Wasserman RL, Sorensen R. Evaluating children with respiratorytract infections: the role of immunization with bacterial polysaccha-ride vaccine. Pediatr Infect Dis J. 1999; 18:157-163.

Huo Z, Spencer O, Miles J, Johnson J, Holliman R, Sheldon J, et al.Antibody response to pneumolysin and to pneumococcal capsularpolysaccharide in healthy individuals and Streptococcus pneumoniaeinfected patients. Vaccine. 2004; 22:1157-61.

Obaro SK, Adegbola RA, Chang I, Banya WA, Jaffar S, Mcadam K,et al. Safety and immunogenicity of a nonavalent pneumococcal vac-cine conjugated to CRM 197 administered simultaneously but in aseparate syringe with diphtheria, tetanus and pertussis vaccines inGambian infants. Pediatr Infect Dis J. 2000; 19: 463-469.

Dagan R, Kaythty H, Wuorimaa T, Yaich M, Bailleux F, Zamir O, etal. Tolerability and immunogenicity of an eleven valent mixed carri-er Streptococcus pneumoniae capsular polysaccharide-diphtheria tox-oid or tetanus protein conjugate vaccine in Finnish and Israeli infants.Pediatr Infect Dis J. 2004; 23:91-98.

Whitney C, Farley M, Hadler J, Harrison L, Bennett NM, Lynfield R,et al. Decline in invasive pneumococcal disease after the introductionof protein-polysaccharide conjugate vaccine. N Engl J Med. 2003;348:1737-46.

Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen J, et al.Efficacy, safety and immunogenicity of heptavalent pneumococcalconjugate vaccine in children. Pediatr Infect Dis J. 2000; 19: 187-195.

Black S, Shinefield H, Baxter R, Austrian R, Bracken L, Hansen J, etal. Postlicensure surveillance for pneumococcal invasive disease afteruse of heptavalent pneumococcal conjugate vaccine in NorthernCalifornia Kaiser Permanente. Pediatr Infect Dis J. 2004; 23: 485-489.

Palmu AI, Verho J, Jokinen J, Karma P, Kilpi T. The seven valentpneumococcal conjugate vaccine reduces tympanostomy tube place-mente in children. Pediatr Infect Dis J. 2004; 23:732-738.

Hausdorff W, Yothers G, Dagan R, Kilpi T, Pelton S, Cohen R, et al.Multinacional study of pneumococcal serotypes causing acute otitismedia in children. Pediatr Infect Dis J. 2002; 21:1008-16.

Dagan R, Givon-Lavi N, Shkolnik L, Yagupsky P, Fraser D. Acuteotitis media caused by antibiotic-resistant Streptococcus pneumoniaein southern Israel: implication for immunizing with conjugate vac-cines. J Infect Dis. 2000; 181:1322-9.

Fireman B, Black SB, Shinefield HR, Lee J, Lewis E, Ray P. Impactof the pneumococcal conjugate vaccine on otitis media. Pediatr InfectDis J. 2003; 22:10-6.

Arguedas A, Loaiza C, Pérez A, Vargas F, Herrera M, Rodríguez G, etal. Microbiology of otitis media in Costa Rican children. PediatrInfect Dis J. 1998; 17:680-9.

Porat N, Arguedas A, Spratt B, Trefler R, Brilla E, Loaiza C, et al.Emergence of penicillin nonsusceptible Streptococcus pneumoniaeclones of non-vaccine serotypes: Serotype 11A and 15B/C variants ofresistant clones of serotypes included in the pneumococcal conjugatevaccines. J Infect Dis. 2004; 190:2154-2161.

Descargas

Publicado

2006-04-01

Cómo citar

Sierra Fernández, H., Shultz Faingezicht, M., Soley Gutiérrez, C., Guevara Jiménez, S., & Arguedas Mhos, A. (2006). Estado actual de la vacuna conjugada contra Streptococcus Pneumoniae. Acta Médica Costarricense, 48(2), 66–71. https://doi.org/10.51481/amc.v48i2.243

Artículos similares

También puede {advancedSearchLink} para este artículo.